anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Open sublay and laparoscopic IPOM repair have specific disadvantages and risks. In recent years, this evidence led to a paradigm shift and induced the development of new minimally invasive techniques of sublay mesh repair.
METHODS: Pioneering this trend, we developed the endoscopically assisted mini- or less-open sublay (MILOS) concept. The operation is performed trans-hernially via a small incision with light-holding laparoscopic instruments either under direct, or endoscopic visualization. After dissection of an extra-peritoneal space of at least 8 cm, port placement and CO2 insufflation, each MILOS operation can be continued endoscopically (EMILOS repair). All E/MILOS operations were prospectively documented in the Herniamed Registry with 1- and 5-year questionnaire follow-ups. Propensity score matching of incisional hernia operations comparing the results of the E/MILOS operation with the laparoscopic intraperitoneal onlay mesh operation (IPOM) and open sublay repair from all other institutions participating in the Herniamed Registry was performed. The results with perioperative complications and 1-year follow-up have been published previously.
RESULTS: This paper reports on the 5-year results. The 5-year follow-up rate was 87.5% (538 of 615 patients with E/MILOS incisional hernia operations). Comparing E/MILOS repair with laparoscopic IPOM and open sublay operation, propensity score matching analysis was possible with 448 and 520 pairs of operations, respectively. Compared with laparoscopic IPOM incisional hernia operation, the E/MILOS repair is associated with significantly fewer general complications (P = 0.004), recurrences (P < 0.001), less pain on exertion (P < 0.001), and less chronic pain requiring treatment (P = 0.016) and tends to result in fewer postoperative complications (P = 0.052), and less pain at rest (P = 0.053). Matched pair analysis with open sublay repair revealed significantly fewer general complications (P < 0.001), postoperative complications (P < 0.001), recurrences (P = 0.002), less pain at rest (P = 0.004), less pain on exertion (P < 0.001), and less chronic pain requiring treatment (P = 0.014). A limitation of this analysis is a relative low 5-year follow-up rate for laparoscopic IPOM and open sublay.
CONCLUSIONS: The E/MILOS technique allows minimally invasive trans-hernial repair of incisional hernias using large standard meshes with low morbidity and good long-term results. The technique combines the advantages of sub-lay repair and a mini- or less-invasive approach.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03133000.
This study is evaluating the performance of various bandages on facilitating the healing of induced dermabrasion wounds. To qualify for this study, subjects must meet the inclusion/exclusion criteria within the protocol-specified parameters at both the screening and baseline visits. Once a subject is qualified, five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages and one wound will be left open to the air to serve as a no treatment control. Treatments and control will be randomized to application site. During this 14-day clinical study, subjects will return to the site for daily evaluations; study bandages will also be replaced daily by study personnel. Adverse events will be observed and collected by querying each subject at each visit, and during any follow-up period.
The invention relates to a method for analyzing a health exposure reaction relation of haze weather population based on Web, which comprises the following steps: firstly, the method comprises the following steps: and setting the name of the city to be analyzed on a Web interface and uploading the personal data of the crowd health of the city. II, secondly: and (4) setting a crowd screening condition to be analyzed on a Web interface, and screening individual cases meeting the condition by the system and converting the individual cases into statistical data organized in an ascending order of date. Thirdly, the method comprises the following steps: the data is automatically associated. Fourthly, the method comprises the following steps: and setting initial conditions of the analysis model on a Web interface. Fifthly: and automatically generating and executing an analysis code of the R language by the background according to the analysis condition set by the analyst, and returning the haze weather crowd health exposure reaction relation value and the residual error map obtained by analysis under the model setting to the Web interface for displaying. Sixthly, the method comprises the following steps: and according to the returned result, the analysis model parameters are adjusted on the Web interface according to the requirement, and then the interactive analysis execution process is visualized again until the result meets the service requirement. The method has scientific conception, high operability and strong universality.
PROBLEM TO BE SOLVED: To obtain a melanogenesis inhibitor having high tyrosinase activity- inhibiting action and melanogenesis suppressing action, excellent in beautifying effect and useful for preventing and improving pigmentation after sunburn, liver spot, freckles, etc., by including a specific tocopherol derivative as an active ingredient. SOLUTION: This melanogenesis inhibitor comprises a tocopherol derivative of the formula (R is a sugar residue selected from glucose and maltose), [e.g. dl-α-tocopherylglucoside] as an active ingredient. The compound of the formula is obtained by subjecting, e.g. a tocopherol such as dl-α-tocopherol to heat reaction with a peracetylated glucose such as D-glucose-pentaacetylate in a solvent such as dibutyldiethylene glycol at a high temperature for about 2-5 hr to carry out deacetylation. The agent is useful as an ingredient of skin preparation for external use for beautifying such as cosmetics, medicines for external use.
The antibiotic activity of moenomycin complex (Specification 977,327) or its components A, B and C against gram-positive pathogenic germs is enhanced by hydrogenation. The hydrogenation is carried out with the aid of precious metal catalysts (e.g. platinum) or Raney nickel in a polar solvent such as water, glacial acetic acid, methanol or dimethyl formamide. In the case of the hydrogenated moenomycin complex, the complex may be separated into the hydrogenated single components A, B and C by the process of Specification 1,126,196. Physical data for the hydrogenated compounds are provided. Pharmaceutical compositions comprise a carrier and a hydrogenated moenomycin complex or hydrogenated component A, B or C.
<P>PROBLEM TO BE SOLVED: To obtain an agent for preventing and treating disorder of blood sugar regulation, having new mechanism of action.  <P>SOLUTION: A composition for preventing and treating the disorder of the blood sugar regulation contains a modifier of expression and/or activity of a CDK (cyclin dependent kinase)-inhibiting factor. The method for screening a material capable of preventing and treating the disorder of the blood sugar regulation involves evaluating whether or not a material to be tested regulates the expression and/or the activity of the CDK-inhibiting factor. The agent for preventing and treating the disorder of the blood sugar regulation is obtained by the method. A nonhuman mammal from which a causative gene of the hereditary disorder of the blood sugar regulation and a CDK-inhibiting factor gene are deleted is also provided.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The extraction of impacted wisdom teeth in patients forming this study arm was performed using the Gow-Gates anesthesia technique. In these patients, the distance between the wisdom teeth and the inferior alveolar nerve is greater than 1 mm.
The invention relates to a wireless device for medical data transmission that comprises a wireless interface, a processor, and a medical equipment interface arranged to provide connection to an item of medical equipment. The processor is arranged to communicate with the medical equipment interface and the wireless interface, and is also 5 arranged to perform a protocol adaptation. The protocol adaptation takes place from a protocol of inco ming data received at the medical equipment interface to a protocol of data to be transmitted through the wireless interface, or vice versa. The protocol adaptation comprises individual or combined filtering, gathering, partitioning, prioritizing, or discarding the incoming data. The processor is further arranged to read a configuration file containing an 10 adaptation specification that pertains to the protocol adaptation; and to perform the protocol adaptation in compliance with the adaptation specification. The invention also relates to a method for setting up the wireless device.
PROBLEM TO BE SOLVED: To obtain an odorless and safe disinfectant, containing specific compounds prepared by purification from an extract solution of tea leaves such as green tea or black tea as an active ingredient, having disinfecting and sterilizing effects on fungi, spore bearing bacteria, viruses, etc., and nontoxic to humans and animals. SOLUTION: This composition contains catechins as an active ingredient or is obtained by blending the catechins in a disinfectant consisting essentially of alcohols. The blending ratio of the catechins is 100-1,000ppm. The catechins are obtained by removing caffeine and pigments in, e.g. green tea leaves of medium quality with chloroform, then extracting a portion soluble in ethyl acetate, subsequently freeze-drying the resultant extract to obtain crude catechins and then fractionating and purifying the crude catechins by a means such as high-performance liquid chromatography. This disinfectant manifests effects on methicillin-resistant Staphylococcus aureus that is a causative bacterium of nosocomial infection, influenza viruses causing influenza, rotaviruses causing infantile diarrheal symptoms, polioviruses causing paralysis, coxsackieviruses, etc. causing rash, etc.
Chronic exposure to high-altitude hypoxic environments may influence short-term memory and working memory. However, its impact on long-term memory, specifically episodic memory, remains understudied. In this study, we systematically investigated the effects of long-term exposure to high altitude (3650 m) on episodic memory, including item memory and source memory. Moreover, we examined the moderating role of daytime dysfunction on the relationship between altitude and episodic memory. In total, 97 participants were enrolled in the study: 49 were from the high-altitude (HA) group, comprising those born and raised in low altitude (LA) areas (< 500 m) and had migrated to HA for 2∼3 years after turning 18; and 48 were from the LA group, who had never lived at high altitudes. Episodic memory was evaluated using a what-when-where task, whereas daytime dysfunction was measured by the Pittsburgh Sleep Quality Index. For item memory, hit rate and correct rejection rate were significantly lower in the HA group relative to the LA group. For source binding memory, the performance in what-where binding and what-when-where binding were decreased in the HA group, but the what-when binding did not differ between the two groups. Furthermore, the effects of altitude on hit rate, what-where binding, and what-when-where binding were significantly pronounced in individuals with higher levels of daytime dysfunction. These findings suggest that long-term exposure to high-altitude hypoxic environments influences episodic memory performance, including item recognition and source-binding memory. Specifically, spatial source memory is affected by high-altitude exposure, whereas temporal source memory remains unaffected. Moreover, these results highlight the importance of considering sleep quality, especially good daytime function, in maintaining optimal episodic memory function following chronic exposure to high altitudes.
The invention relates to a recombinant plasmid DNA (deoxyribonucleic acid) vaccine. The recombinant plasmid DNA vaccine carries a hepatitis B surface antigen protein encoding gene and a hepatitis B core antigen protein encoding gene. The constructed recombinant plasmid DNA vaccine comprises two target protein expression boxes, wherein one of the two target protein expression boxes is an optimized target protein expression box. The two genes are separated from each other by one target protein expression box. The invention further relates to a dual-plasmid DNA vaccine. The dual-plasmid DNA vaccine comprises the recombinant plasmid DNA vaccine and a recombinant interleukin-12 adjuvant plasmid. The constructed recombinant plasmid DNA vaccine and the composition thereof can be used for preparing a medicament for preventing and treating hepatitis B.
AZT may not be the optimal antiretroviral agent for all pregnant women requiring therapy for HIV infection. Although ddI has been approved for use in HIV-infected adults and older children, the safety and pharmacokinetics of ddI in pregnant women has not yet been determined.

Patients receive a single IV dose of ddI on day 1 and pharmacokinetics values are determined. At least 48 hours but no more than 1 week after the IV dose, patients receive an oral dose, and oral pharmacokinetics are obtained for 8 hours. Oral ddI is then administered every 12 hours until labor commences and then after delivery, every 12 hours until 6 weeks postpartum. During labor and delivery, patients receive a loading dose of ddI followed by continuous infusion. Pharmacokinetics are obtained during infusion and also at 6 weeks postpartum. AS PER AMENDMENT 11/24/97: Maternal IV pharmacokinetic studies will not be performed after ddI IV formulation has expired (11/30/97). Maternal and cord samples will be required regardless of whether mother has received continuous IV ddI during labor.
Tobacco exposure is known to be associated with a higher prevalence and incidence of liver diseases. Cotinine, a metabolite of nicotine, is a typical indicator of tobacco exposure. However, the relationship of serum cotinine levels with hepatic steatosis and liver fibrosis remains controversial and these relationships need more research to explored in American teenagers. Cross-sectional data included 1433 participants aged 12-19 from the National Health and Nutrition Examination Survey (NHANES) from 2017 to 2020 were thoroughly used for this study. The linear relationships between serum cotinine levels and the Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP) were examined using multiple linear regression models. Subgroup analysis, interaction tests, and nonlinear interactions were also carried out. Serum cotinine levels > 2.99 ng/ml [β = 0.41 (0.07, 0.76), p = 0.018] and 0.05-2.99 ng/ml [β = 0.24 (0.00, 0.49), p = 0.048] showed a significant positive connection with LSM in multivariate linear regression analysis when compared to serum cotinine levels ≤ 0.05 ng/ml (p for trend = 0.006). Moreover, we discovered an inverted U-shaped association of log2-transformed cotinine with LSM with an inflection point of 4.53 using a two-stage linear regression model. However, according to multiple regression analysis, serum cotinine and CAP did not significantly correlate (p = 0.512). In conclusion, this study demonstrated that smoking cessation and keep away from secondhand smoking may beneficial for liver health in American teenagers.
The invention belongs to the field of natural product xanthine oxidase inhibitors, and relates to application of isoflavone alcohol and 5,7-dihydroxycoumarin in preparation of medicines taking xanthine oxidase as a target point. Experiments prove that the activities of the isoflavone alcohol and the 5,7-dihydroxycoumarin for inhibiting XO in vitro are IC  50  The values represent 8.45.+ -. 0.68. Mu.M and 10.91.+ -. 0.71. Mu.M, respectively, which are equivalent to the existing clinical allopurinol inhibiting XO activity in vitro. Meanwhile, compared with the prior clinical medicine allopurinol, the cytotoxicity of the isoflavone alcohol and the 5,7-dihydroxycoumarin to L-O2 cells is obviously reduced. The invention provides more choices for the development of xanthine oxidase inhibitors and medicines for treating hyperuricemia or gout.
In this paper we investigate the generation of phenotypes for kidney transplant donors and recipients to assist with decision making around organ allocation. We present an ensemble clustering approach for multi-type data (numerical and categorical) using two different clustering approaches-i.e., model based and vector quantization based clustering. These clustering approaches were applied to a large, US national deceased donor kidney transplant recipient database to characterize members of each cluster (in an unsupervised fashion) and to determine whether the subsequent risk of graft failure differed for each cluster. We generated three distinct clusters of recipients, which were subsequently used to generate phenotypes. Each cluster phenotype had recipients with varying clinical features, and the risk of kidney transplant graft failure and mortality differed across clusters. Importantly, the clustering results by both approaches demonstrated a significant overlap. Utilization of two distinct clustering approaches may be a novel way to validate unsupervised clustering techniques and clustering can be used for organ allocation decision making on the basis of differential outcomes.
Up to 15 subjects will enroll in this imaging study at the University of Pennsylvania. Those with a diagnosis of a new intra-axial brain mass that is consistent with GBM per the opinion of a Penn neuroradiologist OR New contrast-enhancing lesion or lesions showing increased enhancement (\>25% increase) in a patient with a historical diagnosis of glioblastoma.
Personal disability identity is a predictor of psychosocial functioning among adults with predominantly physical disabilities. In the present study, we examined personal disability identity in adults with learning disabilities (LD) and/or attention-deficit/hyperactivity disorder (ADHD). In samples of 541 adults with LD, 475 with ADHD, and 433 with comorbid LD and ADHD, we examined the structural validity of disability acceptance and disability affirmation scores and the association between these scores and anxiety/depression, life satisfaction, and general self-efficacy. Factor analyses supported a 4-item disability acceptance and 3-item disability affirmation scale in LD-only and ADHD-only samples. Among adults with LD or ADHD, disability affirmation was a meaningful predictor of life satisfaction, and disability acceptance predicted general self-efficacy. Disability identity attitudes are worthy of clinical and scholarly attention in adults with LD and ADHD, and adults with comorbid LD and ADHD may warrant special consideration in the personal disability identity literature.
The invention relates to the field of medicines, and discloses a medicinal composition for treating the Parkinson disease. The medicinal composition comprises the active component of panaxtrial saponins. Preferably, the panaxtrial saponins comprises 60-80wt% of ginsenoside Rg1, 5-15wt% of ginsenoside Re, 10-25wt% of notoginsenoside R1 in content. The panaxtrial saponins has effects on inhibiting SH-SY5Y cell viability loss caused by 6-hydroxydopamine in a dosage dependency mode and inhibiting PC12 cell apoptosis induced by MPP+, and has an obvious effect on inhibiting SH-SY5Y cell viability loss caused by 6-OHDA. Animal experiments show that the dopamine content is reduced in the corpus striatum of a Parkinson mouse model by the inhibition effect of the panaxtrial saponins in a dosage dependency mode. The results show that the panaxtrial saponins have a new application in preparing the medicine for treating the Parkinson disease and have a favorable clinical application prospect.
Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Guedel oral airway first and measurements were taken during breaths 6 through 10. After its removal the Articulated Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
A stent is provided in combination with delivery of a tocopherol agent, and in particular a des-methyl tocopherol agent, and further beneficially a gamma-tocopherol agent, so as to reduce restenosis along the vessel or other lumenal wall where the stent is implanted. In particular applications, the stent is an endolumenal stent, and more specific beneficial applications is an endovascular stent, and the gamma-tocopherol elutes from a coating or carrier coupled with the stent. Certain combinations are provided with the des-methyl-tocopherol or phytyl substituted chromanol, e.g. gamma-tocopherol, combined with an additional agent such as an anti-restenosis agent, e.g. sirolimus, tacrolimus, everolimus, or paclitaxel, in order to provide synergistic benefit to tissues along the stented or recanalized regions. Other forms of tocopherol or tocotrienol, or other phytyl substituted chromanols, and other compounds such as palm oil, are also contemplated, for use to treat restenosis.
A composition comprising a novel Ca 2+ -activated, [ATP] i -sensitive nonspecific cation (NC Ca-ATP ) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca] i . The NC Ca-ATP  channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NC Ca-ATP  channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NC Ca-ATP  channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described.